Indications and Purposes
| 1 Indications And Usage Spritam Is Indicated For Adjunctive Therapy In The Treatment Of: Partial Onset Seizures In Patients With Epilepsy 4 Years Of Age And Older Weighing More Than 20 Kg ( 1.1 ) Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy ( 1.2 ) Primary Generalized Tonic-Clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy ( 1.3 ) 1.1 Partial Onset Seizures Spritam Is Indicated As Adjunctive Therapy In The Treatment Of Partial Onset Seizures In Patients With Epilepsy 4 Years Of Age And Older Weighing More Than 20 Kg. 1.2 Myoclonic Seizures In Patients With Juvenile Myoclonic Epilepsy Spritam Is Indicated As Adjunctive Therapy In The Treatment Of Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Spritam Is Indicated As Adjunctive Therapy In The Treatment Of Primary Generalized Tonic‑clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Levetiracetam |
|
ZINC1547851 |